The decision on the covid-19 vaccine from Astra Zeneca, which applied for registration with the European Medicines Agency (EMA) on Tuesday, could be issued by the end of January, according to the State Institute for Drug Control (SÚKL). According to the schedule from the vaccination strategy, the Czechia expects to deliver 200,000 doses in February, and three million by the end of the year. Together with the Pfizer / BioNTech vaccine, which cannot be vaccinated by doctors in routine surgeries due to storage conditions, they make up the majority of deliveries scheduled for this year.
“Thanks to the fact that the vaccine is associated with an easier way of handling and storage, vaccination will become more accessible. It is another step so that we can return to normal life,” said SÚKL director Irena Storová.
If approved, the vaccine will be the third authorized for the European market. For the first vaccine from Pfizer and BioNTech, the EMA and the EC approved conditional use last December 21, and the vaccine arrived in the Czech Republic five days later. The second from Moderna was on January 6 and the first delivery arrived in the Czech Republic on Tuesday. Pharmaceutical companies produce batches of the vaccine before its final approval, so that they can then deliver them to specific countries more quickly on the basis of orders.
According to the schedule, 277,875 doses of vaccine from the Pfizer BioNTech company are to arrive in the Czech Republic in January; According to the original orders, 80,000 doses were to arrive from Moderna, while 20,000 doses have been promised so far. The first 8400 arrived in the Czech Republic on Tuesday.
In February, approximately 360,000 to 433,000 doses from Pfizer / BioNTech are expected, so far 80,000 doses from Moderna and 200,000 doses from Astra Zeneca. The vaccination strategy counts on 400,000 in March, 500,000 in April and 900,000 in May. It should be more than three million doses by the end of the year.
Last year, the European Commission signed an agreement with Astra Zeneca as the first manufacturer. Experts believed that it would reach the registration first, in addition to having the lowest price of all ordered. While the EU costs 1.78 euros (about 46 crowns) from Astra Zenca, 12 euros (314 crowns) from Pfizer and $ 18 (about 385 crowns) from Moderna Like the Pfizer / BioNTech consortium, Astra Zeneca is offering the European Commission a further increase in supply.
The Astra Zeneca vaccine, which is already being vaccinated in Britain, for example, is a recombinant vaccine that is made from a virus that causes colds in chimpanzees. It is given in two doses, with an interval of 28 days between applications. It is stored at temperatures of two to eight degrees Celsius and has a one-year shelf life under these conditions. According to clinical studies, its effectiveness is 70 percent, with up to 90 percent at the second dose, but the studies have not yet been completed.
By the end of this year, the Czech Republic has ordered 6.8 million to 7.3 million doses of vaccine, depending on the number of doses obtained from one vial from Pfizer / BioNTech. Of these, three million are currently from Astra Zeneca and 2.7 to 3.3 million from Pfizer / BioNTech. Most manufacturers require two doses.
*The article has been translated based on the content of Tyden.cz by www.tyden.cz. If there is any problem regarding the content, copyright, please leave a report below the article. We will try to process as quickly as possible to protect the rights of the author. Thank you very much!
*We just want readers to access information more quickly and easily with other multilingual content, instead of information only available in a certain language.
*We always respect the copyright of the content of the author and always include the original link of the source article.If the author disagrees, just leave the report below the article, the article will be edited or deleted at the request of the author. Thanks very much! Best regards!